---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332802"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-08-04T20:09:52+00:00"
generated_at: "2026-08-04T20:11:33.493619+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q2 revenue $214M, net loss narrows to $0.90/share; reaffirms 2026 guidance

## Summary
- Q2 total revenue $214M (up 28% YoY); Crysvita $156M, Dojolvi $27M, Evkeeza $21M, Mepsevii $10M.
- Net loss $92M ($0.90/share) vs $115M ($1.17) in Q2 2025; operating expenses $289M.
- Reaffirms FY2026 revenue guidance $730M-$760M; combined R&D/SG&A flat to slightly down vs 2025; on track for profitability in 2027.
- Upcoming catalysts: PDUFA for DTX401 (Aug 23) and UX111 (Sep 19); GTX-102 Phase 3 data in Sep/Oct 2026.
- Cash $436M; net cash used in operations $97M in Q2.

## SEC filing metadata
- accession: 0001193125-26-332802
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-08-04T20:09:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/0001193125-26-332802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332802
- JSON: https://secwatch.observer/filing/0001193125-26-332802.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.